Jupiter Neurosciences
JUNS----
Jupiter Neurosciences (JUNS)
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous sy...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Jupiter Neurosciences Analyst Rating
View MoreForecast & Rating
Aug 22, 2025Price forecast
$30.0024693.39%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 15 hours ago
The 2026 Biotech Divide: When Generative Biology Meets the FDA Wall
- PUBT · 1 day ago, 08:13 PM
Jupiter Neurosciences director Andrew Jon Cutler files initial beneficial ownership statement
- benzinga_article · 2 days ago, 07:05 AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Global Report · 2 days ago, 04:17 AM
Tech Pivots to Cloud Mega-Deals as AI Momentum Spills Into Biopharma
- US Stock Market Update · Jul 21 at 02:40 PM
Jupiter Neurosciences climbs 5% on $100M ALA-002 licensing deal
- US Stock Market Update · Jul 21 at 12:01 PM
Jupiter Neurosciences jumps 4% on $100M drug licensing deal
